UNSPSC 51432110: Guanethidine monosulfate

This classification denotes an antihypertensive agent with the molecular structure C10H22N4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5UBY8Y002G chemically known as guanidine, (2-(hexahydro-1(2h)-azocinyl)ethyl)-, sulfate (1:1), but more commonly known as guanethidine monosulfate, which bears US NIH Compound Identifier 3518. European Medicines Agency schedules Guanethidine monosulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14033MIG.

Most nations, for tariff and trade purposes, schedule guanethidine monosulfate under HS 29339990 and SITC 51577. As of Q4 2014, GUANETHIDINE MONOSULFATE remains US FDA's Preferred Term for this commodity. Guanethidine monosulfate bears US NLM identifiers UMLS ID C0282190 and NCI Concept Code C65831. SMILES: C1CCCN(CCC1)CCNC(=N)N.OS(=O)(=O)O.

UNSPSC 51432110 Guanethidine monosulfate (Commodity) covers pharmaceutical active ingredients and finished medications procured by state and local emergency-response and healthcare organizations, though recent state and local solicitations under this code show limited activity focused on pre-formulated emergency medical supplies rather than the raw chemical compound itself. State and local buyers under this code include fire rescue departments, emergency medical services divisions, and municipal healthcare procurement offices that source medications for advanced life support protocols, typically through sealed-bid processes with firm pricing and expiration-date warranties. The work being solicited involves supplying specific medication line items in unit quantities, meeting storage and replacement requirements, and complying with OSHA hazard communication and federal accessibility standards.

The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue in Hillsborough County, Florida, with a response deadline of April 8, 2026 — a date that has already passed as of the summary date. The solicitation called for four specific medication line items (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem) totaling approximately 3,530 units, with an estimated contract value of $40,000.00, a one-year term with two one-year renewal options, and a Small Local Business Enterprise (SLBE) sheltered-market designation offering a 5 percent bid discount not to exceed $10,000. Beyond this Florida opportunity, the source supports no other recent state or local solicitations under this code, indicating minimal current activity or procurement frequency in this Commodity category.